Mathematical modeling of atopic dermatitis reveals “double‐switch” mechanisms underlying 4 common disease phenotypes

Background The skin barrier acts as the first line of defense against constant exposure to biological, microbial, physical, and chemical environmental stressors. Dynamic interplay between defects in the skin barrier, dysfunctional immune responses, and environmental stressors are major factors in the development of atopic dermatitis (AD). A systems biology modeling approach can yield significant insights into these complex and dynamic processes through integration of prior biological data. Objective We sought to develop a multiscale mathematical model of AD pathogenesis that describes the dynamic interplay between the skin barrier, environmental stress, and immune dysregulation and use it to achieve a coherent mechanistic understanding of the onset, progression, and prevention of AD. Methods We mathematically investigated synergistic effects of known genetic and environmental risk factors on the dynamic onset and progression of the AD phenotype, from a mostly asymptomatic mild phenotype to a severe treatment‐resistant form. Results Our model analysis identified a “double switch,” with 2 concatenated bistable switches, as a key network motif that dictates AD pathogenesis: the first switch is responsible for the reversible onset of inflammation, and the second switch is triggered by long‐lasting or frequent activation of the first switch, causing irreversible onset of systemic TH2 sensitization and worsening of AD symptoms. Conclusions Our mathematical analysis of the bistable switch predicts that genetic risk factors decrease the threshold of environmental stressors to trigger systemic TH2 sensitization. This analysis predicts and explains 4 common clinical AD phenotypes from a mild and reversible phenotype through to severe and recalcitrant disease and provides a mechanistic explanation for clinically demonstrated preventive effects of emollient treatments against development of AD. Graphical abstract Figure. No caption available.

[1]  W. Paul,et al.  Independent roles for IL-2 and GATA-3 in stimulating naive CD4+ T cells to generate a Th2-inducing cytokine environment , 2005, The Journal of experimental medicine.

[2]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[3]  S. Wakana,et al.  Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. , 2016, The Journal of clinical investigation.

[4]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[5]  Stephen J. Galli,et al.  The development of allergic inflammation , 2008, Nature.

[6]  L. Beck,et al.  Innate immune defects in atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[7]  P. Ahmad-Nejad,et al.  The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. , 2004, The Journal of allergy and clinical immunology.

[8]  D. Koenig,et al.  Immediate and extended effects of sodium lauryl sulphate exposure on stratum corneum natural moisturizing factor , 2014, International journal of cosmetic science.

[9]  Thomas B. Clarke,et al.  Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. , 2009, The Journal of clinical investigation.

[10]  Manuel A. R. Ferreira,et al.  Multi-ethnic genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis , 2015, Nature Genetics.

[11]  A. Wollenberg,et al.  Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema , 2012, Annals of dermatology.

[12]  D. Koenig,et al.  Immediate and extended effects of abrasion on stratum corneum natural moisturizing factor , 2015, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[13]  Prabir Ray,et al.  A critical role for NF-κB in Gata3 expression and TH2 differentiation in allergic airway inflammation , 2001, Nature Immunology.

[14]  H. Dommisch,et al.  Protease-Activated Receptor 2 Mediates Human Beta-Defensin 2 and CC Chemokine Ligand 20 mRNA Expression in Response to Proteases Secreted by Porphyromonas gingivalis , 2007, Infection and Immunity.

[15]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[16]  M. Akiyama,et al.  Clinical severity correlates with impaired barrier in filaggrin-related eczema. , 2009, The Journal of investigative dermatology.

[17]  M. Ono,et al.  Skin Barrier Homeostasis in Atopic Dermatitis: Feedback Regulation of Kallikrein Activity , 2011, PloS one.

[18]  M. Zasloff Antimicrobial peptides of multicellular organisms , 2002, Nature.

[19]  Stephan Weidinger,et al.  Atopic dermatitis , 2016, The Lancet.

[20]  T. Jean,et al.  Variability In Measurement Of Allergen Skin Testing Results Among Allergy-Immunology Specialists , 2014 .

[21]  A. Irvine,et al.  Filaggrin mutations associated with skin and allergic diseases. , 2011, The New England journal of medicine.

[22]  A. Borkowski,et al.  TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. , 2011, The Journal of investigative dermatology.

[23]  R. Tazi-Ahnini,et al.  New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. , 2006, The Journal of allergy and clinical immunology.

[24]  A. Irvine,et al.  The multifunctional role of filaggrin in allergic skin disease. , 2013, The Journal of allergy and clinical immunology.

[25]  Kazuyuki Aihara,et al.  Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer. , 2010, Chaos.

[26]  P. Dubus,et al.  Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome , 2009, The Journal of experimental medicine.

[27]  K. Barnes,et al.  Cytokine modulation of atopic dermatitis filaggrin skin expression. , 2007, The Journal of allergy and clinical immunology.

[28]  K. Cease,et al.  Staphylococcus δ-toxin induces allergic skin disease by activating mast cells , 2013, Nature.

[29]  Masahiro Ono,et al.  Skin disease modeling from a mathematical perspective. , 2013, The Journal of investigative dermatology.

[30]  M. Cork,et al.  The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis , 2014, The British journal of dermatology.

[31]  K. Asadullah,et al.  Glucocorticoid therapy‐induced skin atrophy , 2006, Experimental dermatology.

[32]  K. Nakanishi,et al.  Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice , 2013, Proceedings of the National Academy of Sciences.

[33]  C. Gieger,et al.  Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects , 2013, The Journal of allergy and clinical immunology.

[35]  G. Imokawa,et al.  Reevaluation of the non-lesional dry skin in atopic dermatitis by acute barrier disruption: an abnormal permeability barrier homeostasis with defective processing to generate ceramide , 2014, Archives of Dermatological Research.

[36]  Matias Ostrowski,et al.  Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions , 2014, Front. Immunol..

[37]  P. Fallon,et al.  Macrophage and Innate Lymphoid Cell Interplay in the Genesis of Fibrosis , 2015, Front. Immunol..

[38]  Colin N A Palmer,et al.  Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis , 2006, Nature Genetics.

[39]  A. Taïeb,et al.  Biologics in atopic dermatitis , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[40]  A. Shiohama,et al.  A homozygous frameshift mutation in the murine filaggrin gene facilitates enhanced percutaneous allergen priming , 2009, Nature Genetics.

[41]  Diego A Oyarzún,et al.  Multistability and oscillations in genetic control of metabolism. , 2012, Journal of theoretical biology.

[42]  T. Ganz,et al.  Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. , 2008, The Journal of investigative dermatology.

[43]  D. Ioannides,et al.  Investigation of cytokine levels and their association with SCORAD index in adults with acute atopic dermatitis , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  Bodo Grimbacher,et al.  STAT3 mutations in the hyper-IgE syndrome. , 2007, The New England journal of medicine.

[45]  A. Buret,et al.  PAR2 activation alters colonic paracellular permeability in mice via IFN‐γ‐dependent and ‐independent pathways , 2004, The Journal of physiology.

[46]  R. Gallo,et al.  The Role of the Skin Microbiome in Atopic Dermatitis , 2015, Current Allergy and Asthma Reports.

[47]  S. Kežić,et al.  Intragenic Copy Number Variation within Filaggrin Contributes to the Risk of Atopic Dermatitis with a Dose-Dependent Effect , 2011, The Journal of investigative dermatology.

[48]  Min Chen,et al.  Regulation of the lifespan in dendritic cell subsets. , 2007, Molecular immunology.

[49]  Kenneth R Feingold,et al.  pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. , 2003, The Journal of investigative dermatology.

[50]  P. Elias,et al.  Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[51]  M. Suárez-Fariñas,et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[52]  Grant Lythe,et al.  How many dendritic cells are required to initiate a T-cell response? , 2012, Blood.

[53]  R. Unger,et al.  Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT , 2014, Bone Marrow Transplantation.

[54]  S. Kežić,et al.  Atopic dermatitis and skin disease Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency , 2012 .

[55]  S. Akira,et al.  Enhanced apoptosis by disruption of the STAT3-IκB-ζ signaling pathway in epithelial cells induces Sjögren's syndrome-like autoimmune disease. , 2013, Immunity.

[56]  H. Williams,et al.  Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention , 2014, The Journal of allergy and clinical immunology.

[57]  Thomas Bieber,et al.  Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? , 2014, The Journal of allergy and clinical immunology.

[58]  D. Leung,et al.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.

[59]  A. Schmidtchen,et al.  Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin‐associated microbial antigens in adult patients with atopic dermatitis , 2014, International journal of dermatology.

[60]  P. Elias,et al.  Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. , 2008, The Journal of investigative dermatology.

[61]  J. Spergel Epidemiology of atopic dermatitis and atopic march in children. , 2010, Immunology and allergy clinics of North America.

[62]  Reiko J. Tanaka,et al.  Resistance to Water Diffusion in the Stratum Corneum Is Depth-Dependent , 2015, PloS one.

[63]  Richard A Flavell,et al.  The Transcription Factor GATA-3 Is Necessary and Sufficient for Th2 Cytokine Gene Expression in CD4 T Cells , 1997, Cell.

[64]  Julia Oh,et al.  Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis , 2012, Genome research.

[65]  Mauricio Barahona,et al.  Risk factor-dependent dynamics of atopic dermatitis: modelling multi-scale regulation of epithelium homeostasis , 2013, Interface Focus.

[66]  H. Wong,et al.  The role of the skin barrier in modulating the effects of common skin microbial species on the inflammation, differentiation and proliferation status of epidermal keratinocytes , 2013, BMC Research Notes.

[67]  F. Chew,et al.  Global Allergy Forum and 3rd Davos Declaration 2015 , 2016, Allergy.

[68]  H. Mizuno,et al.  Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. , 2012, The Journal of allergy and clinical immunology.

[69]  Kazuyuki Aihara,et al.  Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers , 2012, Scientific Reports.

[70]  Takashi Sasaki,et al.  Application of moisturizer to neonates prevents development of atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[71]  J. Sundberg,et al.  Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. , 2009, The Journal of allergy and clinical immunology.

[72]  Andreas Radbruch,et al.  GATA-3 transcriptional imprinting in Th2 lymphocytes: A mathematical model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Kumiko Morita Application of moisturizer to neonates prevents development of atopic dermatitis , 2015, The World Allergy Organization Journal.